Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.

A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.

Cai Y, Lee YF, Li G, Liu S, Bao BY, Huang J, Hsu CL, Chang C.

Int J Cancer. 2008 Jul 1;123(1):195-201. doi: 10.1002/ijc.23481.

2.

Medical therapy of prostate cancer. A review.

Roscigno M, Sangalli M, Mazzoccoli B, Scattoni V, Da Pozzo L, Rigatti P.

Minerva Urol Nefrol. 2005 Jun;57(2):71-84. Review.

PMID:
15951731
3.

Androgen action in the prostate gland.

Yadav N, Heemers HV.

Minerva Urol Nefrol. 2012 Mar;64(1):35-49. Review.

PMID:
22402316
4.

[Keyrole of endocrinology in the victory against prostate cancer].

Labrie F.

Bull Cancer. 2006 Sep;93(9):949-58. Review. French.

5.

Androgen receptor as a target in androgen-independent prostate cancer.

Balk SP.

Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9. Review.

PMID:
12231070
6.

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, Su LC.

J Biomed Sci. 2011 Aug 23;18:63. doi: 10.1186/1423-0127-18-63. Review.

7.

Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

Knudsen KE, Scher HI.

Clin Cancer Res. 2009 Aug 1;15(15):4792-8. doi: 10.1158/1078-0432.CCR-08-2660. Review.

8.

New hormonal therapies for castration-resistant prostate cancer.

Mostaghel EA, Plymate S.

Endocrinol Metab Clin North Am. 2011 Sep;40(3):625-42, x. doi: 10.1016/j.ecl.2011.05.013. Review.

9.

Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution.

Gauthier-Landry L, BĂ©langer A, Barbier O.

J Steroid Biochem Mol Biol. 2015 Jan;145:187-92. doi: 10.1016/j.jsbmb.2014.05.009. Review.

PMID:
24861263
10.

Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.

Silberstein JL, Taylor MN, Antonarakis ES.

Curr Urol Rep. 2016 Apr;17(4):29. doi: 10.1007/s11934-016-0584-4. Review.

11.

Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer.

Peehl DM, Feldman D.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):307-15. Review.

PMID:
15663994
13.

Targeting the eicosanoid pathway in non-small-cell lung cancer.

Horn L, Backlund M, Johnson DH.

Expert Opin Ther Targets. 2009 Jun;13(6):675-88. doi: 10.1517/14728220902915567. Review.

14.

Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.

Bernard MP, Bancos S, Sime PJ, Phipps RP.

Curr Pharm Des. 2008;14(21):2051-60. Review.

15.

The role of transcription factors in prostate cancer and potential for future RNA interference therapy.

Fitzgerald KA, Evans JC, McCarthy J, Guo J, Prencipe M, Kearney M, Watson WR, O'Driscoll CM.

Expert Opin Ther Targets. 2014 Jun;18(6):633-49. doi: 10.1517/14728222.2014.896904. Review.

PMID:
24660778
Items per page

Supplemental Content

Support Center